Long-Term Treatment with Bevacizumab for Patients with Metastatic Colorectal Cancer: Case Report

    loading  Checking for direct PDF access through Ovid

Abstract

Bevacizumab is a monoclonal antibody to vascular endothelial growth factor that has demonstrated increased overall survival when added to standard chemotherapy regimens for metastatic colorectal cancer. Herein we report the cases of 2 patients who demonstrated prolonged survival times of almost 5 and 6 years, respectively, on various chemotherapy regimens that also included bevacizumab. Throughout most of their disease course, these patients maintained a good quality of life, with some adjustments of chemotherapy doses because of side effects. Bevacizumab was generally well tolerated in long-term use.

Clinical Colorectal Cancer, Vol. 6, No. 1, 66–69, 2006

Related Topics

    loading  Loading Related Articles